On the heels of positive early Phase I/II data for bleeding control during coronary artery bypass graft (CABG) surgery, Dyax Corp. said it has agreed to sell about 5.2 million shares for $7.93 each, raising about $41.4 million pursuant to a shelf registration. (BioWorld Today) Read More
